Cardiol therapeutics reports results of 2025 annual general meeting of shareholders

Toronto, ontario--(newsfile corp. - may 29, 2025) - cardiol therapeutics inc. (nasdaq: crdl) (tsx: crdl) ("cardiol" or the "company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its annual general meeting of shareholders (the "agm") held virtually via live audio webcast on may 28, 2025. shareholders voted overwhelmingly in favour of all management resolutions proposed in the company's management information circular dated april 10, 2025.
GM Ratings Summary
GM Quant Ranking